ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
A Multicenter Evaluation of Probiotic Use for the Primary Prevention of Clostridioides difficile Infection.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Clinical Guidance and Practical Recommendations for Probiotic Use in Patients With Irritable Bowel Syndrome, Functional Constipation, andJournal of neurogastroenterology and motility · 2026Review
- Clinical guidance and practical recommendations for probiotic use in patients with irritable bowel syndrome, functional constipation, and Clostridioides difficile infection considering sex-based differences: a Korean translation.Ewha medical journal · 2026Article
- Impact of a Three-Strain Lactobacilli Probiotic (BioK+) on Incidence of Hospital-OnsetAntibiotics (Basel, Switzerland) · 2025Article
- Patient with Inflammatory Bowel Disease in a Dental Office-Which Antibiotic to Choose?-Narrative Review.Journal of clinical medicine · 2025Review
- Article
- Non-invasive treatment ofFrontiers in microbiology · 2025Article
- A Review of Therapies forAntibiotics (Basel, Switzerland) · 2024Review
- Review
- Gut Microbiota-Gut Metabolites andMetabolites · 2024Review
- Host Immune Responses toTropical medicine and infectious disease · 2023Review
- Article
- Lactobacillus rhamnosus a cause of Gram-positive rods bacteremia after prophylactic probiotic consumption.New microbes and new infections · 2023Article
- Probiotics: insights and new opportunities forCritical reviews in microbiology · 2023Review
- Controversies in the Prevention and Treatment ofMicroorganisms · 2023Review
- A Single-Center, Retrospective Cohort Study Evaluating the Use of Probiotics for the Prevention of Hospital-OnsetHospital pharmacy · 2023Article
- Unveiling the inhibition mechanism ofFrontiers in microbiology · 2023Article
- Concurrent and Subsequent Co-Infections ofMicroorganisms · 2022Review
- Why 2 Studies That Used the Same Probiotic May Have Come Up With Different Outcomes.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Editorial: Microbial interactions ofFrontiers in microbiology · 2022Article
- Influence of Probiotics on the Development ofPharmacy (Basel, Switzerland) · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary prevention of Clostridioides difficile infection (CDI) is a priority for hospitals. Probiotics have the potential to interfere with colonization and CDI. In this study, we evaluated the impact of a computerized clinical decision support (CCDS) tool to prescribe probiotics for primary prevention of CDI among adult hospitalized patients.
methodsA CCDS tool was implemented into the electronic medical record at 4 hospitals to prompt prescription of a probiotic preparation at the time of antibiotic prescription in high-risk patients in May 2019. Interrupted time series using segmented regression analysis was conducted to evaluate hospital-wide CDI incidence for the year pre- and post-CCDS implementation. In addition, multivariable logistic regression was used to evaluate CDI incidence in patients who qualified for probiotics in the pre- vs post-intervention periods, adjusting for potential confounders. To adjust for potential differences in patients who received probiotics in the post-intervention period, propensity score-matched pairs were developed to evaluate CDI risk by receipt of probiotics.
resultsQuarterly CDI incidence increased over time post-intervention relative to baseline trends (slope change, 1.4; 95% confidence interval [CI], .9-1.9). The odds ratio (OR) of CDI was 1.41 in eligible patients post-intervention compared with pre-intervention (adjusted OR, 1.41; 95% CI, 1.11-1.79). Propensity score-matched analysis showed that patients who received probiotics did not have lower rates of CDI compared with those who did not receive probiotics (OR, 1.46; 95% CI, .87-2.45).
conclusionsUse of probiotics for primary prevention of CDI among adult inpatients receiving antibiotics is not supported.
Indexed as
Identifiers
33972996What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.